Literature DB >> 31045648

Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV.

Rosan A van Zoest1,2, Matthew Law3, Caroline A Sabin4, Ilonca Vaartjes5, Marc van der Valk6, Joop E Arends7, Peter Reiss1,2,6,8, Ferdinand W Wit1,2,6,8.   

Abstract

BACKGROUND: People living with HIV (PLWH) experience a higher cardiovascular disease (CVD) risk. Yet, traditional algorithms are often used to estimate CVD risk. We evaluated the performance of 4 commonly used algorithms.
SETTING: The Netherlands.
METHODS: We used data from 16,070 PLWH aged ≥18 years, who were in care between 2000 and 2016, had no pre-existing CVD, had initiated first combination antiretroviral therapy >1 year ago, and had available data on CD4 count, smoking status, cholesterol, and blood pressure. Predictive performance of 4 algorithms [Data Collection on Adverse Effects of Anti-HIV Drugs Study (D:A:D); Systematic COronary Risk Evaluation adjusted for national data (SCORE-NL); Framingham CVD Risk Score (FRS); and American College of Cardiology and American Heart Association Pooled Cohort Equations (PCE)] was evaluated using a Kaplan-Meier approach. Model discrimination was assessed using Harrell's C-statistic. Calibration was assessed using observed-versus-expected ratios, calibration plots, and Greenwood-Nam-D'Agostino goodness-of-fit tests.
RESULTS: All algorithms showed acceptable discrimination (Harrell's C-statistic 0.73-0.79). On a population level, D:A:D, SCORE-NL, and PCE slightly underestimated, whereas FRS slightly overestimated CVD risk (observed-versus-expected ratios 1.35, 1.38, 1.14, and 0.92, respectively). D:A:D, FRS, and PCE best fitted our data but still yielded a statistically significant lack of fit (Greenwood-Nam-D'Agostino χ ranged from 24.57 to 34.22, P < 0.05). Underestimation of CVD risk was particularly observed in low-predicted CVD risk groups.
CONCLUSIONS: All algorithms perform reasonably well in PLWH, with SCORE-NL performing poorest. Prediction algorithms are useful for clinical practice, but clinicians should be aware of their limitations (ie, lack of fit and slight underestimation of CVD risk in low-risk groups).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31045648     DOI: 10.1097/QAI.0000000000002069

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study.

Authors:  Derek Larson; Seung Hyun Won; Anuradha Ganesan; Ryan C Maves; Karl Kronmann; Jason F Okulicz; Xiuping Chu; Christina Schofield; Thomas O'Bryan; Brian K Agan; Robert Deiss
Journal:  HIV Med       Date:  2021-10-26       Impact factor: 3.180

2.  Predicting the risk of atherosclerotic cardiovascular disease among adults living with HIV/AIDS in Addis Ababa, Ethiopia: A hospital-based study.

Authors:  Minyahil Woldu; Omary Minzi; Workineh Shibeshi; Aster Shewaamare; Ephrem Engidawork
Journal:  PLoS One       Date:  2021-11-29       Impact factor: 3.240

3.  The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV.

Authors:  Ifedioranma Anikpo; Afiba Manza-A Agovi; Matthew J Cvitanovich; Frank Lonergan; Marc Johnson; Rohit P Ojha
Journal:  HIV Med       Date:  2021-08-19       Impact factor: 3.094

Review 4.  Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations.

Authors:  Amit C Achhra; Asya Lyass; Leila Borowsky; Milana Bogorodskaya; Jorge Plutzky; Joseph M Massaro; Ralph B D'Agostino; Virginia A Triant
Journal:  Curr HIV/AIDS Rep       Date:  2021-07-11       Impact factor: 5.071

5.  Heart Rate Variability, HIV and the Risk of Cardiovascular Diseases in Rural South Africa.

Authors:  Noortje G Godijk; Alinda G Vos; Vita W Jongen; Robert Moraba; Hugo Tempelman; Diederick E Grobbee; Roel A Coutinho; Walter Devillé; Kerstin Klipstein-Grobusch
Journal:  Glob Heart       Date:  2020-02-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.